A case of rheumatoid arthritis/sjogren’s syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy

Japanese Journal of Clinical Immunology

Volumn 27, Issue 3, 2004, Pages 171-176

  Tanaka, Hiroki ^a   Abe, Takashi ^a   Nishimura, Susumu ^a   Sakai, Hajime ^a   Kimura, Hirokazu ^a   Oki, Mariko ^a   Nojima, Masanori ^a   Taga, Masako ^a   Matsumoto, Shin Ichiroh ^a   Takahashi, Hiroki ^a   Imai, Kohzoh ^b  

^a Kushiro City General Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute renal failure; Hyperuricemia; Mizoribine; Rheumatoid arthritis; Sj gren s syndrome

Indexed keywords

4 (ACETYLAMINO)BENZENEACETIC ACID; 4-(ACETYLAMINO)BENZENEACETIC ACID; ETODOLAC; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLACETIC ACID DERIVATIVE; PREDNISOLONE; RIBONUCLEOSIDE;

ACUTE KIDNEY FAILURE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HUMAN; HYPERURICEMIA; MIDDLE AGED; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; ETODOLAC; FEMALE; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, ACUTE; MIDDLE AGED; PHENYLACETATES; PREDNISOLONE; RIBONUCLEOSIDES; SJOGREN'S SYNDROME;

EID: 4143058241     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.27.171     Document Type: Article

References (16)

1. Sakaguchi, K., et al.: Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells. J. Antibiot. 29: 1320–1327, 1976.
2. Koyama, H., et al.: Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem. Pharmacol. 32: 3547–3553, 1983.
3. Kusumi, T., et al.: Dual inhibitory effect of bredinin. Cell Biochemistry and Function 7: 201–204, 1988.
4. Turka, L. A., et al.: Guanin ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J. Clin. Invest. 87: 940–948, 1991.
5. Turka, L. A., et al.: Guanin ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. Bredinin 17: 585–593, 1982.
6. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Int. J. Clin. Pharmacol. Ther. Toxicol. 23: 197–199, 1985.
7. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 28: 1353–1357, 1986.
8. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 1. 16: 317–324, 1996.
9. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 1. 31: 1087–1091, 1998.
10. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 1. 14: 218–221, 1995.
11. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 2. 21: 60, 1999.
12. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 40: 429, 1998.
13. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 2. RA 1. 37: 364, 1997.
14. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. Mizoribine 1. 19: 114, 1988.
15. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 1. 34: 959, 2001.
16. Takada, K., et al.: Elimination characteristics of bredinin from patients serum in hemodialysis. Mizoribine. 34: 574–576, 1997.